Propeller Collaboration with AMC Health Aims to Improve COPD Management, Outcomes

Propeller Health and AMC Health are partnering to assist patients with chronic obstructive pulmonary disease (COPD) and asthma manage their disease more efficiently and reduce symptoms, as well as hospital visits.

The multi-year partnership was signed in January and will kick off this month with the launch of two commercial programs and a clinical research study that will look at adherence barriers at large health plans across the United States.

“Our commercial partnership begins with COPD, which is a challenging disease to manage, and it becomes increasingly difficult as it progresses. Most COPD patients are also burdened by comorbidities. Our partnership with AMC Health aims to help leading healthcare systems overcome these challenges through a more connected approach to care,” Propeller Health CEO David Van Sickle said in a press release. “We are also excited about partnering in asthma, including new research made possible through this relationship.”

The platform was designed for optimized compatibility with most of the commonly used inhalers, including controllers and relievers. It is 510(k)-approved to assist with adherence, reduction of symptoms, and prediction of exacerbations in asthma and COPD. Through a combination of inhaler sensors, apps, analytics, personal feedback, and education, the platform tracks patient use, marking the dates and places of use. It can also be set to warn patients, to prompt patients to take their medication, and to alert caregivers about patients who are at risk or in need of medical assistance and might need proactive intervention.

Propeller will continue its existing business in addition to the new partnership, and new customers can now sign up directly with Propeller or through the new AMC Health partnership. Propeller has been used by people with chronic respiratory diseases in more than 40 commercial programs across the country, including healthcare systems, payers, employers, and others.

The two companies will combine Propeller’s expertise in improving medication adherence and predicting disease exacerbations with AMC Health’s expertise in improving outcomes through enhanced clinical efficiency and care coordination.

“Our clinical, technology, and analytics expertise enables us to empower patients to confidently manage their health, and connect them to the most appropriate intervention at the right time. This has a significant impact on patients with chronic health issues such as COPD and asthma,” said AMC Health President and CEO Nesim Bildirici. “Combining AMC Health’s 13 years of real-time virtual care experience with Propeller’s expertise in improving medication adherence supports improved health outcomes and care management efficiencies that substantially benefit patients and their care teams.”